🎉 M&A multiples are live!
Check it out!

Cytek Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cytek Biosciences and other public comps.

See Cytek Biosciences Valuation Multiples

Cytek Biosciences Overview

About Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.


Founded

2014

HQ

United States of America
Employees

676

Website

cytekbio.com

Financials

LTM Revenue $205M

LTM EBITDA $22.1M

EV

$425M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cytek Biosciences Financials

Cytek Biosciences has a last 12-month revenue of $205M and a last 12-month EBITDA of $22.1M.

In the most recent fiscal year, Cytek Biosciences achieved revenue of $193M and an EBITDA of -$4.4M.

Cytek Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cytek Biosciences valuation multiples based on analyst estimates

Cytek Biosciences P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $164M $193M $203M $205M XXX
Gross Profit $79.1M $101M $109M XXX XXX
Gross Margin 48% 52% 54% XXX XXX
EBITDA $9.5M -$4.4M $21.8M $22.1M XXX
EBITDA Margin 6% -2% 11% 11% XXX
Net Profit $3.0M $2.6M -$12.1M XXX XXX
Net Margin 2% 1% -6% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Cytek Biosciences Stock Performance

As of February 7, 2025, Cytek Biosciences's stock price is $5.

Cytek Biosciences has current market cap of $688M, and EV of $425M.

See Cytek Biosciences trading valuation data

Cytek Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$425M $688M XXX XXX XXX XXX $0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cytek Biosciences Valuation Multiples

As of February 7, 2025, Cytek Biosciences has market cap of $688M and EV of $425M.

Cytek Biosciences's trades at 2.1x LTM EV/Revenue multiple, and 19.3x LTM EBITDA.

Analysts estimate Cytek Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cytek Biosciences and 10K+ public comps

Cytek Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $425M XXX XXX XXX
EV/Revenue 2.1x XXX XXX XXX
EV/EBITDA 19.5x XXX XXX XXX
P/E -200.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cytek Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cytek Biosciences Valuation Multiples

Cytek Biosciences's NTM/LTM revenue growth is 8%

Cytek Biosciences's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Cytek Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cytek Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cytek Biosciences and other 10K+ public comps

Cytek Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 5% XXX XXX XXX XXX
EBITDA Margin 11% XXX XXX XXX XXX
EBITDA Growth -594% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 19% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 25% XXX XXX XXX XXX
G&A Expenses to Revenue 23% XXX XXX XXX XXX
R&D Expenses to Revenue 23% XXX XXX XXX XXX
Opex to Revenue 71% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Cytek Biosciences Public Comps

See valuation multiples for Cytek Biosciences public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Philips XXX XXX XXX XXX XXX XXX
Perspective Therapeutics XXX XXX XXX XXX XXX XXX
Electromed XXX XXX XXX XXX XXX XXX
InfuSystem XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cytek Biosciences M&A and Investment Activity

Cytek Biosciences acquired  XXX companies to date.

Last acquisition by Cytek Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cytek Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cytek Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cytek Biosciences

When was Cytek Biosciences founded? Cytek Biosciences was founded in 2014.
Where is Cytek Biosciences headquartered? Cytek Biosciences is headquartered in United States of America.
How many employees does Cytek Biosciences have? As of today, Cytek Biosciences has 676 employees.
Who is the CEO of Cytek Biosciences? Cytek Biosciences's CEO is Dr. Wenbin Jiang, PhD.
Is Cytek Biosciences publicy listed? Yes, Cytek Biosciences is a public company listed on NAS.
What is the stock symbol of Cytek Biosciences? Cytek Biosciences trades under CTKB ticker.
When did Cytek Biosciences go public? Cytek Biosciences went public in 2021.
Who are competitors of Cytek Biosciences? Similar companies to Cytek Biosciences include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem.
What is the current market cap of Cytek Biosciences? Cytek Biosciences's current market cap is $688M
What is the current revenue of Cytek Biosciences? Cytek Biosciences's last 12-month revenue is $205M.
What is the current EBITDA of Cytek Biosciences? Cytek Biosciences's last 12-month EBITDA is $22.1M.
What is the current EV/Revenue multiple of Cytek Biosciences? Current revenue multiple of Cytek Biosciences is 2.1x.
What is the current EV/EBITDA multiple of Cytek Biosciences? Current EBITDA multiple of Cytek Biosciences is 19.3x.
What is the current revenue growth of Cytek Biosciences? Cytek Biosciences revenue growth between 2023 and 2024 was 5%.
Is Cytek Biosciences profitable? Yes, Cytek Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.